2016_Head & Neck COURSE BOOK

Loco regional control and p16 ‐

St. I-II p16+ 90% St. III-IV p16+

St. III-IV p16- St I II . - -

p16 57%

DAHANCA 2000‐2013, curative intent RT, oropharynx patients with known p16 status (n=1163)

Made with